ECSP11011371A - Inhibidor de la map cinasa p38 - Google Patents

Inhibidor de la map cinasa p38

Info

Publication number
ECSP11011371A
ECSP11011371A EC2011011371A ECSP11011371A ECSP11011371A EC SP11011371 A ECSP11011371 A EC SP11011371A EC 2011011371 A EC2011011371 A EC 2011011371A EC SP11011371 A ECSP11011371 A EC SP11011371A EC SP11011371 A ECSP11011371 A EC SP11011371A
Authority
EC
Ecuador
Prior art keywords
inhibitor
map
cinasa
kinase
diseases
Prior art date
Application number
EC2011011371A
Other languages
English (en)
Inventor
Kasuhiro Ito
Peter Strong
William Garth Rapeport
Jonathan Gareth Williams
Stuart Thomas Onions
Peter Jhon Murray
Catherine Charron
Underwood John King
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of ECSP11011371A publication Critical patent/ECSP11011371A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto de la Fórmula (I):o una sal farmacéuticamente aceptable del mismo, incluyendo todos los estereoisómeros y tautómeros, que es un inhibidor de las enzimas de proteína cinasa activadas por mitógeno p38 (en adelante se mencionan como inhibidores de la MAP cinasa p38), en particular sus subtipos de alfa y gamma cinasa, y su uso en terapia, incluyendo en combinaciones farmacéuticas, especialmente en el tratamiento de enfermedades inflamatorias, incluyendo las enfermedades inflamatorias del pulmón, como la EPOC.
EC2011011371A 2009-04-03 2011-10-03 Inhibidor de la map cinasa p38 ECSP11011371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16659409P 2009-04-03 2009-04-03
GBGB0905955.1A GB0905955D0 (en) 2009-04-06 2009-04-06 Novel compounds

Publications (1)

Publication Number Publication Date
ECSP11011371A true ECSP11011371A (es) 2011-11-30

Family

ID=40750191

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011371A ECSP11011371A (es) 2009-04-03 2011-10-03 Inhibidor de la map cinasa p38

Country Status (19)

Country Link
US (2) US8642773B2 (es)
EP (1) EP2414347B1 (es)
JP (1) JP5751640B2 (es)
KR (1) KR20120006033A (es)
CN (1) CN102395575B (es)
AU (1) AU2010231120B2 (es)
CA (1) CA2754609A1 (es)
CL (1) CL2011002442A1 (es)
CO (1) CO6501168A2 (es)
EA (1) EA201171213A1 (es)
EC (1) ECSP11011371A (es)
GB (1) GB0905955D0 (es)
IL (1) IL214799A0 (es)
MX (1) MX2011010366A (es)
NI (1) NI201100173A (es)
PE (1) PE20120516A1 (es)
SG (1) SG174139A1 (es)
WO (1) WO2010112936A1 (es)
ZA (1) ZA201108048B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA105763C2 (uk) 2007-12-19 2014-06-25 Кансер Рісерч Текнолоджі Лімітед 8-ЗАМІЩЕНІ ПІРИДО[2,3-b]ПІРАЗИНИ ТА ЇХ ЗАСТОСУВАННЯ
BRPI0920707A2 (pt) 2008-10-02 2015-12-29 Respivert Ltd compostos
WO2010067130A1 (en) * 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB0921730D0 (en) * 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
US8855064B2 (en) 2010-01-12 2014-10-07 Qualcomm Incorporated Bundled frequency division multiplexing structure in wireless communications
NZ706154A (en) 2010-02-01 2016-09-30 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
JP5787976B2 (ja) 2010-04-08 2015-09-30 レスピバート・リミテツド Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア
EP2582700B1 (en) 2010-06-17 2016-11-02 Respivert Limited Respiratory formulations containing p38 mapk inhibitors
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
GB201010193D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
JP2014528404A (ja) * 2011-10-03 2014-10-27 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤としての１−ピラゾリル−３−（４−（（２−アニリノピリミジン−４−イル）オキシ）ナフタレン−１−イル）尿素
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
EP2890460B1 (en) 2012-08-29 2017-02-22 Respivert Limited Kinase inhibitors
US9783556B2 (en) 2012-08-29 2017-10-10 Respivert Limited Kinase inhibitors
EP2890695A2 (en) 2012-08-29 2015-07-08 Respivert Limited Kinase inhibitors
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
EP2925742B1 (en) 2012-11-16 2016-10-26 Respivert Limited Kinase inhibitors
WO2014140582A1 (en) 2013-03-14 2014-09-18 Respivert Limited Kinase inhibitors
US9771353B2 (en) 2013-04-02 2017-09-26 Topivert Pharma Limited Kinase inhibitors based upon N-alkyl pyrazoles
MX363949B (es) 2013-04-02 2019-04-08 Topivert Pharma Ltd Inhibidor de quinasa.
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2015092423A1 (en) 2013-12-20 2015-06-25 Respivert Limited Urea derivatives useful as kinase inhibitors
EP3105222B1 (en) 2014-02-14 2018-04-11 Respivert Limited Aromatic heterocyclic compounds as antiinflammatory compounds
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
CA3015978A1 (en) 2016-04-06 2017-10-12 Topivert Pharma Limited Kinase inhibitors
CA3142097A1 (en) 2018-05-30 2019-12-05 Washington University Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
WO2021013712A1 (en) 2019-07-19 2021-01-28 Anagenesis Biotechnologies S.A.S. Polyaromatic urea derivatives and their use in the treatment of muscle diseases
EP4029501A1 (en) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1028953A1 (en) 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
ES2154253T3 (es) 1997-12-22 2012-01-27 Bayer Healthcare Llc Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas.
DE69836563T2 (de) 1997-12-22 2007-05-16 Bayer Pharmaceuticals Corp., West Haven INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
EP1047418B1 (en) 1997-12-22 2005-07-27 Bayer Pharmaceuticals Corp. Inhibition of raf kinase using substituted heterocyclic ureas
DE69834842T2 (de) 1997-12-22 2007-05-10 Bayer Pharmaceuticals Corp., West Haven Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
JP2002506873A (ja) 1998-03-18 2002-03-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 複素環式シグナル伝達阻害剤、それを含む組成物
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
PL350357A1 (en) 1999-03-12 2002-12-02 Boehringer Ingelheim Pharma Heterocyclic urea and related compounds useful as anti−inflammatory agents
EP1200411B1 (en) 1999-07-09 2005-12-14 Boehringer Ingelheim Pharmaceuticals Inc. Process for synthesis of heteroaryl-substituted urea compounds
EP1223924A4 (en) 1999-09-17 2004-07-14 Smithkline Beecham Corp USE OF CSAIDS AGAINST RHINOVIRUS INFECTION
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
JP2004518739A (ja) 2001-02-15 2004-06-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤として有用なヘテロアリール置換尿素化合物の合成方法
CA2445003A1 (en) 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
ES2284887T3 (es) 2001-07-11 2007-11-16 Boehringer Ingelheim Pharmaceuticals Inc. Metodos para tratar enfermedades transmitidas por citocinas.
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
JP4629978B2 (ja) * 2002-02-25 2011-02-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療に有用な１，４−二置換ベンゾ縮合シクロアルキル尿素化合物
CN1658834A (zh) 2002-04-05 2005-08-24 贝林格尔英格海姆法玛两合公司 治疗粘液分泌过多的方法
JP2005538975A (ja) 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド ｐ３８ＭＡＰキナーゼ阻害薬としての３−（ヘテロ）アリールメトキシピリジン類およびそれらの類縁体
US20040110755A1 (en) 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
JP2006503025A (ja) 2002-09-05 2006-01-26 サイオス インク． ｐ３８ＭＡＰキナーゼの抑制による疼痛治療
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
ATE489379T1 (de) 2003-02-28 2010-12-15 Bayer Healthcare Llc 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
JP4617299B2 (ja) 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド ｐ３８阻害剤及びその使用法
GB0308511D0 (en) 2003-04-14 2003-05-21 Astex Technology Ltd Pharmaceutical compounds
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
WO2004101529A1 (ja) 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
EP1658060A2 (en) * 2003-08-22 2006-05-24 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating copd and pulmonary hypertension
CA2545711A1 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
WO2005115397A2 (en) 2004-04-29 2005-12-08 Pharmix Corporation Compositions and treatments for modulating kinase and/or hmg-coa reductase
ATE517885T1 (de) 2004-04-30 2011-08-15 Bayer Healthcare Llc Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
US7388021B2 (en) 2004-05-12 2008-06-17 Bristol Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1609789A1 (en) 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
SI1761520T1 (sl) 2004-06-23 2008-10-31 Lilly Co Eli Inhibitorji kinaze
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP1778686B9 (en) 2004-08-12 2009-07-08 Pfizer Limited Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
EP1824843A2 (en) 2004-12-07 2007-08-29 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
US20080081833A1 (en) 2004-12-20 2008-04-03 Astrazeneca Ab Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors
WO2006081034A2 (en) 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
JP5197016B2 (ja) 2004-12-23 2013-05-15 デシファラ ファーマスーティカルズ， エルエルシー 酵素モジュレータ及び治療
GB0500435D0 (en) 2005-01-10 2005-02-16 Novartis Ag Organic compounds
US20070110760A1 (en) 2005-01-14 2007-05-17 Monroe John G Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity
DE102005015253A1 (de) 2005-04-04 2006-10-05 Merck Patent Gmbh Pyrazolderivate
WO2006127678A2 (en) 2005-05-23 2006-11-30 Smithkline Beecham Corporation Inhibition of p38 mark for treatment of obesity
JP5094716B2 (ja) 2005-06-20 2012-12-12 テイボテク・フアーマシユーチカルズ ヘテロシクリルアミノアルキル置換ベンズイミダゾール
ATE485269T1 (de) 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
WO2007038425A2 (en) 2005-09-27 2007-04-05 Regents Of The University Of Minnesota Anti-viral compouinds
TWI325423B (en) 2005-10-28 2010-06-01 Lilly Co Eli Kinase inhibitors
WO2007059202A2 (en) 2005-11-15 2007-05-24 Bayer Healthcare Ag Pyrazolyl urea derivatives useful in the treatment of cancer
JP2009518298A (ja) 2005-12-01 2009-05-07 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療に有用な尿素化合物
ES2378704T3 (es) 2006-01-27 2012-04-17 Array Biopharma, Inc. Activadores de la glucocinasa
CN101374841A (zh) 2006-01-30 2009-02-25 Irm责任有限公司 作为ppar调节剂的螺咪唑衍生物
EP1987022A1 (en) 2006-02-10 2008-11-05 Pfizer Products Inc. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
JP5238697B2 (ja) 2006-08-04 2013-07-17 武田薬品工業株式会社 縮合複素環誘導体およびその用途
CN101686686A (zh) 2007-02-20 2010-03-31 梅里奥尔医药I公司 鉴别Lyn激酶激活剂的方法
EP2131858A4 (en) 2007-03-20 2011-11-23 Cadila Pharmaceuticals Ltd P38 INHIBITORS
AR065858A1 (es) 2007-03-29 2009-07-08 Sanofi Aventis Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona.
WO2008125014A1 (fr) 2007-04-13 2008-10-23 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. Composés d'urée, leurs procédés de préparation et leurs utilisations pharmaceutiques
UA105763C2 (uk) 2007-12-19 2014-06-25 Кансер Рісерч Текнолоджі Лімітед 8-ЗАМІЩЕНІ ПІРИДО[2,3-b]ПІРАЗИНИ ТА ЇХ ЗАСТОСУВАННЯ
PT2303267E (pt) 2008-02-04 2013-08-05 Pfizer Ltd Forma polimórfica de um derivado de [1, 2, 4]triazol[4, 3-a]piridina para tratar doenças inflamatórias
HUE025197T2 (en) 2008-03-17 2016-02-29 Ambit Biosciences Corp Quinazoline derivatives as RAF kinase modulators and methods for their use
CA2731926A1 (en) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
BRPI0920707A2 (pt) 2008-10-02 2015-12-29 Respivert Ltd compostos
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
WO2010067130A1 (en) 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
GB201005589D0 (en) * 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
JP5787976B2 (ja) 2010-04-08 2015-09-30 レスピバート・リミテツド Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
EP2582700B1 (en) 2010-06-17 2016-11-02 Respivert Limited Respiratory formulations containing p38 mapk inhibitors
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods

Also Published As

Publication number Publication date
CN102395575B (zh) 2014-11-12
EA201171213A1 (ru) 2012-03-30
EP2414347B1 (en) 2016-03-30
US9242960B2 (en) 2016-01-26
IL214799A0 (en) 2011-11-30
CA2754609A1 (en) 2010-10-07
GB0905955D0 (en) 2009-05-20
JP5751640B2 (ja) 2015-07-22
WO2010112936A1 (en) 2010-10-07
AU2010231120A1 (en) 2011-09-08
PE20120516A1 (es) 2012-05-09
AU2010231120B2 (en) 2014-01-30
ZA201108048B (en) 2013-04-24
NI201100173A (es) 2012-02-21
US8642773B2 (en) 2014-02-04
SG174139A1 (en) 2011-10-28
KR20120006033A (ko) 2012-01-17
MX2011010366A (es) 2011-10-17
JP2012522760A (ja) 2012-09-27
CL2011002442A1 (es) 2012-04-09
CN102395575A (zh) 2012-03-28
CO6501168A2 (es) 2012-08-15
US20120136031A1 (en) 2012-05-31
EP2414347A1 (en) 2012-02-08
US20140228410A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
ECSP11011371A (es) Inhibidor de la map cinasa p38
CL2020002026A1 (es) Inhibidor de fap.
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
ECSP11010948A (es) Inhibidores de las enzimas de proteína cinasa activadas por
NI201400027A (es) 1 - pirazolil - 3 - ( 4 - (( 2 - anilinopirimidin - 4 - il) oxi) naftalen - 1 - il) ureas como inhibidores de proteínas cinasas activadas por mitógeno p38
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
CL2017003496A1 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
DOP2011000204A (es) Inhibidores de proteina cinasa
PH12018500768A1 (en) Purin derivatives for use in the treatment of fab-related diseases
WO2010067130A8 (en) P38 map kinase inhibitors
PE20160200A1 (es) Inhibidores de bromodominios
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
NI201200061A (es) Derivados de quinazolina-4(3h)-ona utilizados como inhibidores de la cinasa de pi3
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
CO6690816A2 (es) Derivados de quinazolin-4(3h)-ona utilizados como inhibidores de pi3 cinasa
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
MX2017004129A (es) Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2- il)amino-benzoico como inhibidor de quinasa p38.
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
CO6321268A2 (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
UY32710A (es) Nuevos inhibidores de la quinasa map p38
AR088107A1 (es) Derivados de anilinopirimidina y su uso como inhibidores de quinasas p38
JO3130B1 (ar) يوريات 1-بيرازوليل-3- (4 - ((2-أنيلينو بيريميدين-4-ايل) أوكسي) نفثالين-1-ايل) بصفتها مثبطات نوع بي 38 ماب كينيز